Invesco Ltd. has recently announced an increase in its ownership stake in Charles River Laboratories International, Inc., now holding approximately 3.9% of the company. This update, filed on November 10, 2026, is significant as it reflects Invesco's growing interest in the commercial physical and biological research sector, which is crucial for advancements in healthcare and pharmaceuticals.

Background

Charles River Laboratories International, Inc. operates in the Services-Commercial Physical & Biological Research sector, as classified under SIC 8731. The company is publicly traded on the New York Stock Exchange under the ticker CRL. As a large accelerated filer, Charles River Laboratories has been active in filing various forms with the SEC, including recent filings such as 8-Ks and quarterly reports.

What the Filing Says

The Schedule 13G/A filing indicates that Invesco Ltd. beneficially owns 1,852,539 shares of Charles River Laboratories. This includes 1,845,388 shares with sole voting power and 1,852,539 shares with sole dispositive power. The filing states, "Invesco Ltd., in its capacity as a parent holding company to its investment advisers, may be deemed to beneficially own 1,852,539 shares of the Issuer which are held of record by clients of Invesco Ltd." This highlights the investment firm's role in managing assets for various clients.

Impact

This development may affect various stakeholders, including shareholders, clients of Invesco Ltd., and competitors within the commercial physical and biological research industry. The increase in ownership by a prominent investment firm like Invesco could influence market perceptions and shareholder sentiment regarding Charles River Laboratories.

What's Next

The filing does not specify what happens next regarding this ownership change. However, it is likely that stakeholders will monitor any further developments or actions taken by Invesco Ltd. in relation to its stake in Charles River Laboratories.